GlassScriptPhysician profile
Malaz Almsaddi
NPI 1003897562
$24,522.08
in general payments reported to CMS, 2019-2025
71 companies · $2,150 in 2025
The $2,150 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,072 · 2020: $2,355 · 2021: $3,087 · 2022: $4,585 · 2023: $4,684 · 2024: $4,588 · 2025: $2,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,197.76 |
| Education | $224.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,370.65 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Neurocrine Biosciences, INC. | $1,263.27 | 2019-2025 | Ingrezza, Ongentys |
| Biogen, INC. | $1,092.97 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Genzyme Corporation | $1,070.31 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $988.05 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $941.99 | 2019-2025 | |
| Emd Serono, INC. | $810.03 | 2019-2024 | Mavenclad |
| Lilly USA, LLC | $762.45 | 2019-2025 | Emgality, Kisunla, Reyvow |
| Catalyst Pharmaceuticals, INC. | $721.91 | 2020-2025 | Fycompa, Firdapse |
| Sk Life Science, INC. | $689.61 | 2020-2025 | |
| Abbvie INC. | $686.88 | 2019-2025 | Ubrelvy, Duopa, Qulipta |
| Amneal Pharmaceuticals LLC | $665.72 | 2019-2024 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Teva Pharmaceuticals USA, INC. | $641.72 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Pfizer INC. | $633.05 | 2019-2025 | |
| Amgen INC. | $589.26 | 2019-2024 | Uplizna |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malaz Almsaddi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.